R A Luqmani

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. ncbi Towards diagnostic criteria for the ANCA-associated vasculitides
    R A Luqmani
    Botnar Research Centre, University of Oxford, UK
    Clin Exp Rheumatol 25:S57. 2007
  2. ncbi Introduction to, and classification of, the systemic vasculitides
    R A Luqmani
    Rheumatology Department, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK
    Best Pract Res Clin Rheumatol 15:187-202. 2001
  3. ncbi The diagnostic value of anti-neutrophil cytoplasmic antibody testing in a routine clinical setting
    J S McLaren
    Rheumatic Diseases Unit, Western General Hospital, Edinburgh, UK
    QJM 94:615-21. 2001
  4. ncbi Diagnosis and assessment of systemic vasculitis
    J S McLaren
    Department of Rheumatology, University of Edinburgh, UK
    Clin Exp Rheumatol 20:854-62. 2002
  5. ncbi Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again)
    C M Deighton
    Rheumatology (Oxford) 45:649-52. 2006
  6. ncbi The role of biologic therapies in the management of systemic vasculitis
    A T Chan
    Rheumatology Department, Nuffield Orthopaedic Centre, Windmill Road, Headington Oxford OX3 7LD, UK
    Autoimmun Rev 5:273-8. 2006
  7. ncbi Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
    O Flossmann
    Ann Rheum Dis 65:841-4. 2006
  8. ncbi Clinical and biological assessment in systemic necrotizing vasculitides
    C B Mukhtyar
    Botnar Research Centre, University of Oxford, UK
    Clin Exp Rheumatol 24:S92-9. 2006
  9. ncbi Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force
    C Mukhtyar
    Botnar Research Centre, University of Oxford, Windmill Road, Oxford OX3 7LD, UK
    Ann Rheum Dis 67:1004-10. 2008

Collaborators

Detail Information

Publications9

  1. ncbi Towards diagnostic criteria for the ANCA-associated vasculitides
    R A Luqmani
    Botnar Research Centre, University of Oxford, UK
    Clin Exp Rheumatol 25:S57. 2007
  2. ncbi Introduction to, and classification of, the systemic vasculitides
    R A Luqmani
    Rheumatology Department, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK
    Best Pract Res Clin Rheumatol 15:187-202. 2001
    ..Classification systems should assist in the determination of therapy and prediction of outcomes, but have many limitations, which are discussed further in this review...
  3. ncbi The diagnostic value of anti-neutrophil cytoplasmic antibody testing in a routine clinical setting
    J S McLaren
    Rheumatic Diseases Unit, Western General Hospital, Edinburgh, UK
    QJM 94:615-21. 2001
    ..The PPV of ANCA by IIF/ELISA for AASV was 79% and the NPV was 63%. The ANCA test is being widely applied with very poor return. Guidelines for more effective usage are proposed...
  4. ncbi Diagnosis and assessment of systemic vasculitis
    J S McLaren
    Department of Rheumatology, University of Edinburgh, UK
    Clin Exp Rheumatol 20:854-62. 2002
    ..The increasing use of surrogate clinical measures of disease should provide a greater opportunity to establish the effectiveness of existing and novel therapies in the management of these complex diseases...
  5. ncbi Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again)
    C M Deighton
    Rheumatology (Oxford) 45:649-52. 2006
  6. ncbi The role of biologic therapies in the management of systemic vasculitis
    A T Chan
    Rheumatology Department, Nuffield Orthopaedic Centre, Windmill Road, Headington Oxford OX3 7LD, UK
    Autoimmun Rev 5:273-8. 2006
    ..We examine the rationale for using biologics based on the pathophysiology of vasculitis. Issues of toxicity and pharmacovigilance with the use of biologics are also discussed. Finally, future directions and predictions are presented...
  7. ncbi Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
    O Flossmann
    Ann Rheum Dis 65:841-4. 2006
  8. ncbi Clinical and biological assessment in systemic necrotizing vasculitides
    C B Mukhtyar
    Botnar Research Centre, University of Oxford, UK
    Clin Exp Rheumatol 24:S92-9. 2006
    ..Clinical Assessment tools are the current gold standard for the assessment of disease activity, damage and function...
  9. ncbi Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force
    C Mukhtyar
    Botnar Research Centre, University of Oxford, Windmill Road, Oxford OX3 7LD, UK
    Ann Rheum Dis 67:1004-10. 2008
    ....